Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01854957 (ClinicalTrials.gov)	July 2012	8/5/2013	MEsenchymal StEm Cells for Multiple Sclerosis	MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous Mesenchymal Stem Cells	Antonio Uccelli	Azienda Ospedaliera Universitaria Integrata Verona;Ospedale San Raffaele	Recruiting	18 Years	50 Years	Both	20	Phase 1/Phase 2	Italy
2	EUCTR2012-000518-13-DK (EUCTR)	21/06/2012	21/06/2012	Own mesenchymal stem cells for multiple sclerosis patients	Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study - COMSCIMS	Multiple sclerosis MedDRA version: 18.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mesenchymal stem/stromal cells Product Name: Mesenchymal stem cells (MSCs)	Prof. Per Soelberg Sørensen	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark